PL371014A1 - Pochodne 6-fluorobicyklo [3.1.0] heksanu - Google Patents

Pochodne 6-fluorobicyklo [3.1.0] heksanu

Info

Publication number: PL371014A1
Authority: PL; Poland
Prior art keywords: group; alkoxy; represent; fluorobicyclo; different
Prior art date: 2001-12-27

Application number

PL02371014A

Other languages

English (en)

Other versions

PL208123B1 (pl

Inventor

Atsuro Nakazato

Shigeyuki Chaki

Kazunari Sakagami

Ryoko Dean

Hiroshi Ohta

Shiho Hirota

Akito Yasuhara

Original Assignee

Taisho Pharmaceutical Co,Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-27

Filing date

2002-12-26

Publication date

2005-06-13

2002-12-26 Application filed by Taisho Pharmaceutical Co,Ltd. filed Critical Taisho Pharmaceutical Co,Ltd.

2005-06-13 Publication of PL371014A1 publication Critical patent/PL371014A1/pl

2011-03-31 Publication of PL208123B1 publication Critical patent/PL208123B1/pl

Links

CGRSIAQTWWBUEJ-UHFFFAOYSA-N 6-fluorobicyclo[3.1.0]hexane Chemical class C1CCC2C(F)C21 CGRSIAQTWWBUEJ-UHFFFAOYSA-N 0.000 title 1
125000002252 acyl group Chemical group 0.000 abstract 2
125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 1
125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000003042 antagnostic effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
239000000935 antidepressant agent Substances 0.000 abstract 1
229940005513 antidepressants Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
- C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Heat Sensitive Colour Forming Recording (AREA)
Lubricants (AREA)
Glass Compositions (AREA)

PL371014A 2001-12-27 2002-12-26 Pochodna kwasu 2-amino-3-alkoksy-6-fluorobicyklo [3.1.0] heksano-2, 6-dikarboksylowego, zawierająca ją kompozycja farmaceutyczna i lek, oraz jej zastosowanie PL208123B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2001395797		2001-12-27

Publications (2)

Publication Number	Publication Date
PL371014A1 true PL371014A1 (pl)	2005-06-13
PL208123B1 PL208123B1 (pl)	2011-03-31

Family

ID=27602080

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL371014A PL208123B1 (pl)	2001-12-27	2002-12-26	Pochodna kwasu 2-amino-3-alkoksy-6-fluorobicyklo [3.1.0] heksano-2, 6-dikarboksylowego, zawierająca ją kompozycja farmaceutyczna i lek, oraz jej zastosowanie

Country Status (23)

Country	Link
US (1)	US7157594B2 (pl)
EP (1)	EP1459765B1 (pl)
JP (1)	JP4230919B2 (pl)
KR (2)	KR20090031962A (pl)
CN (1)	CN1281274C (pl)
AT (1)	ATE405289T1 (pl)
AU (1)	AU2002359923B2 (pl)
BR (1)	BR0215462A (pl)
CA (1)	CA2471642C (pl)
CY (1)	CY1108380T1 (pl)
DE (1)	DE60228491D1 (pl)
DK (1)	DK1459765T3 (pl)
ES (1)	ES2311642T3 (pl)
HU (1)	HU228436B1 (pl)
MX (1)	MXPA04006322A (pl)
NO (1)	NO328844B1 (pl)
NZ (1)	NZ533699A (pl)
PL (1)	PL208123B1 (pl)
PT (1)	PT1459765E (pl)
RU (1)	RU2315622C2 (pl)
SI (1)	SI1459765T1 (pl)
WO (1)	WO2003061698A1 (pl)
ZA (2)	ZA200404795B (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7939087B2 (en) *	2000-10-27	2011-05-10	Novartis Vaccines And Diagnostics, Inc.	Nucleic acids and proteins from Streptococcus groups A & B
HRP20041179B1 (hr) *	2002-06-11	2012-11-30	Eli Lilly And Company	Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti
US7109383B2 (en) *	2002-09-27	2006-09-19	Central Glass Company, Limited	Fluorine-containing allyl ether compounds, their copolymers, and resist compositions and anti-reflection film materials using such copolymers
EP2123630B1 (en) *	2003-06-26	2012-07-25	Taisho Pharmaceutical Co., Ltd	2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative
JP5485492B2 (ja) *	2004-12-15	2014-05-07	大正製薬株式会社	うつ病の予防・治療薬
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
EP2314289A1 (en)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
AR059898A1 (es)	2006-03-15	2008-05-07	Janssen Pharmaceutica Nv	Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
EP2021000A2 (en)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenesis by modulating angiotensin
US7678808B2 (en)	2006-05-09	2010-03-16	Braincells, Inc.	5 HT receptor mediated neurogenesis
WO2008030651A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200922566A (en)	2007-09-14	2009-06-01	Ortho Mcneil Janssen Pharm	1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
EA017648B1 (ru)	2007-09-14	2013-02-28	Орто-Макнейл-Янссен Фармасьютикалз, Инк.	1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
BRPI0816970A2 (pt)	2007-09-14	2015-03-24	Ortho Mcneil Janssen Pharm	1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
CA2704436C (en)	2007-11-14	2016-01-05	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5547194B2 (ja)	2008-09-02	2014-07-09	ジャンセンファーマシューティカルズ，インコーポレイテッド．	代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
WO2010043396A1 (en)	2008-10-16	2010-04-22	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja)	2008-11-28	2015-03-25	ジャンセンファーマシューティカルズ，インコーポレイテッド．	代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh)	2009-05-12	2015-05-13	杨森制药有限公司	1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
HRP20131122T1 (hr)	2009-05-12	2013-12-20	Janssen Pharmaceuticals, Inc.	Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
EP2502897B1 (en)	2009-11-18	2014-07-09	Taisho Pharmaceutical Co., Ltd.	Method for producing optically active bicyclo [3.1.0]hexane derivative using enzyme
US8642777B2 (en) *	2009-11-19	2014-02-04	Taisho Pharmaceutical Co., Ltd	Process for producing 3-alkoxy-2-amino-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative and intermediate thereof
ES2536433T3 (es)	2010-11-08	2015-05-25	Janssen Pharmaceuticals, Inc.	Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852664B2 (ja)	2010-11-08	2016-02-03	ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド	１，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
EP2661435B1 (en)	2010-11-08	2015-08-19	Janssen Pharmaceuticals, Inc.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
AR083845A1 (es)	2010-11-18	2013-03-27	Lilly Co Eli	COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
CN103209954B (zh)	2010-11-18	2015-09-02	伊莱利利公司	作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物
KR101598679B1 (ko)	2011-06-17	2016-02-29	일라이 릴리 앤드 캄파니	mGlu2 수용체 효능제로서의 비시클로(3.1.0)헥산-2,6-디카르복실산 유도체
WO2013062680A1 (en) *	2011-10-25	2013-05-02	Braincells, Inc.	Novel compounds and compositions thereof for treating nervous system disorders
RU2496495C2 (ru) *	2011-12-05	2013-10-27	Учреждение Российской академии медицинских наук Научно-исследовательский институт нормальной физиологии имени П.К. Анохина РАМН	ПРИМЕНЕНИЕ СЕЛЕКТИВНОГО АНТАГОНИСТА ГЛУТАМАТНЫХ РЕЦЕПТОРОВ Ro-256981 ДЛЯ НАПРАВЛЕННОГО ВЛИЯНИЯ НА КОГНИТИВНЫЕ ФУНКЦИИ
EP2857385B1 (en) *	2012-06-01	2017-08-02	Taisho Pharmaceutical Co., Ltd.	Prodrug of fluorine-containing amino acid
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PL3096790T3 (pl)	2014-01-21	2020-01-31	Janssen Pharmaceutica, N.V.	Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
ME03518B (me)	2014-01-21	2020-04-20	Janssen Pharmaceutica Nv	Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
MY195208A (en)	2016-04-18	2023-01-11	Taisho Pharmaceutical Co Ltd	Prodrug of Amino Acid Derivative
JP7314494B2 (ja) *	2017-10-17	2023-07-26	大正製薬株式会社	アミノ酸誘導体のプロドラッグを含有する医薬
JP2024004505A (ja) *	2020-11-26	2024-01-17	大正製薬株式会社	アミノ酸誘導体の製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA969485B (en)	1995-11-16	1998-05-12	Lilly Co Eli	Excitatory amino acid receptor antagonists.
WO1997017950A1 (en)	1995-11-16	1997-05-22	Eli Lilly And Company	Shoulder prosthesis
ZA983930B (en) *	1997-05-14	1999-11-08	Lilly Co Eli	Excitatory amino acid receptor modulators.
DE69918136T2 (de)	1998-08-31	2005-07-07	Taisho Pharmaceutical Co., Ltd.	6-Fluorobicyclo[3.1.0]Hexan-Derivate
JP4194715B2 (ja)	1998-08-31	2008-12-10	大正製薬株式会社	６−フルオロビシクロ［３．１．０］ヘキサン誘導体
CH694053A5 (de)	1998-09-03	2004-06-30	Hoffmann La Roche	Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
NZ516467A (en) *	1999-06-30	2004-03-26	Prescient Neuropharma Inc	A method of treating diseases of the central nervous system (CNS) with 2-aminoindane analogues
MXPA02011053A (es)	2000-05-11	2004-08-19	Kenneth Curry	Compuestos novedosos de carboxi amino espiro (2,4)heptano y derivados de los mismos.
CN1216038C (zh)	2000-06-28	2005-08-24	大正制药株式会社	新型二羧酸衍生物
EP1379511B1 (en) *	2001-04-12	2005-07-20	F. Hoffmann-La Roche Ag	DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II

2002
- 2002-12-26 PL PL371014A patent/PL208123B1/pl unknown
- 2002-12-26 CA CA2471642A patent/CA2471642C/en not_active Expired - Fee Related
- 2002-12-26 DK DK02793421T patent/DK1459765T3/da active
- 2002-12-26 NZ NZ533699A patent/NZ533699A/en not_active IP Right Cessation
- 2002-12-26 SI SI200230736T patent/SI1459765T1/sl unknown
- 2002-12-26 EP EP02793421A patent/EP1459765B1/en not_active Expired - Lifetime
- 2002-12-26 PT PT02793421T patent/PT1459765E/pt unknown
- 2002-12-26 MX MXPA04006322A patent/MXPA04006322A/es active IP Right Grant
- 2002-12-26 AT AT02793421T patent/ATE405289T1/de active
- 2002-12-26 ES ES02793421T patent/ES2311642T3/es not_active Expired - Lifetime
- 2002-12-26 WO PCT/JP2002/013693 patent/WO2003061698A1/ja not_active Ceased
- 2002-12-26 KR KR1020097005135A patent/KR20090031962A/ko not_active Withdrawn
- 2002-12-26 AU AU2002359923A patent/AU2002359923B2/en not_active Ceased
- 2002-12-26 HU HU0402649A patent/HU228436B1/hu not_active IP Right Cessation
- 2002-12-26 KR KR1020047010069A patent/KR100897970B1/ko not_active Expired - Fee Related
- 2002-12-26 RU RU2004122916/15A patent/RU2315622C2/ru not_active IP Right Cessation
- 2002-12-26 CN CNB02826388XA patent/CN1281274C/zh not_active Expired - Fee Related
- 2002-12-26 US US10/500,101 patent/US7157594B2/en not_active Expired - Fee Related
- 2002-12-26 BR BR0215462-5A patent/BR0215462A/pt not_active IP Right Cessation
- 2002-12-26 JP JP2003561641A patent/JP4230919B2/ja not_active Expired - Fee Related
- 2002-12-26 DE DE60228491T patent/DE60228491D1/de not_active Expired - Lifetime
2004
- 2004-06-16 NO NO20042530A patent/NO328844B1/no not_active IP Right Cessation
- 2004-06-17 ZA ZA2004/04795A patent/ZA200404795B/en unknown
2005
- 2005-03-11 ZA ZA2005/02085A patent/ZA200502085B/en unknown
2008
- 2008-09-29 CY CY20081101068T patent/CY1108380T1/el unknown

Also Published As

Publication number	Publication date
PL208123B1 (pl)	2011-03-31
ZA200404795B (en)	2005-08-31
JPWO2003061698A1 (ja)	2005-05-19
KR100897970B1 (ko)	2009-05-18
MXPA04006322A (es)	2004-10-04
RU2004122916A (ru)	2005-03-27
HU228436B1 (en)	2013-03-28
DE60228491D1 (en)	2008-10-02
SI1459765T1 (sl)	2009-02-28
CN1610557A (zh)	2005-04-27
NO328844B1 (no)	2010-05-25
US7157594B2 (en)	2007-01-02
HUP0402649A2 (hu)	2005-10-28
CY1108380T1 (el)	2014-02-12
US20050119345A1 (en)	2005-06-02
DK1459765T3 (da)	2008-10-06
AU2002359923B2 (en)	2007-12-20
JP4230919B2 (ja)	2009-02-25
ES2311642T3 (es)	2009-02-16
PT1459765E (pt)	2008-10-03
WO2003061698A1 (en)	2003-07-31
KR20090031962A (ko)	2009-03-30
ATE405289T1 (de)	2008-09-15
CN1281274C (zh)	2006-10-25
KR20040068348A (ko)	2004-07-30
NO20042530L (no)	2004-09-22
NZ533699A (en)	2006-05-26
HK1073258A1 (en)	2005-09-30
BR0215462A (pt)	2004-11-30
CA2471642C (en)	2011-05-24
NO20042530D0 (no)	2004-06-16
CA2471642A1 (en)	2003-07-31
EP1459765A1 (en)	2004-09-22
ZA200502085B (en)	2005-08-31
RU2315622C2 (ru)	2008-01-27
EP1459765A4 (en)	2006-05-31
EP1459765B1 (en)	2008-08-20

Publication	Publication Date	Title
ZA200502085B (en)	2005-08-31	6-fluorobicyclo[3.1.0]hexane derivatives
ATE193828T1 (de)	2000-06-15	Hypoglykämische dihydrochalconderivate
WO2002010154A3 (en)	2002-06-27	Substituted heterocyclic amides
ATE223378T1 (de)	2002-09-15	Prolineamid-derivate
AU2001274806A1 (en)	2001-12-24	Sulfonamide derivatives
ATE268751T1 (de)	2004-06-15	Biphenylamidin-derivate
EP1454903A4 (en)	2005-12-21	THIADIAZOLINDERIVAT
AU2001269540A1 (en)	2002-01-30	Serotonin reuptake inhibitors
AU2318600A (en)	2000-08-18	Chondrongenesis promotors and indolin-2-one derivatives
EP1034783A4 (en)	2001-03-28	AMIDE DERIVATIVES
ZA200105886B (en)	2002-01-17	Agent of treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient.
AP2002002595A0 (en)	2002-09-30	Heterocyclic amide derivatives.
AU2001228862A1 (en)	2001-08-14	Remedies or preventives for liver diseases containing diaminotrifluoromethylpyridine derivatives
EP1734046A4 (en)	2009-01-07	radiosensitizer
AU7962000A (en)	2001-05-14	Us0027324for eating disorders
EP1650210A4 (en)	2007-07-18	THERAPEUTIC AGENT AGAINST HYPERKALEMIA AND BONE DISEASE
EP1306368A3 (en)	2003-07-02	3,4-dihydro-1H-naphtalene derivatives as a highly selective cyclooxygenase-2 inhibitor
WO2004000206A3 (en)	2004-03-25	Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same
DE60001205D1 (de)	2003-02-20	Azolderivative oder deren Salze
ATE289601T1 (de)	2005-03-15	Benzopyran derivate und diese enthaltende antiallergisches mittel